Biologicals in childhood severe asthma: the European PERMEABLE survey on the<i>status quo</i>

Abstract

Substantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident.